EU Reference Medicinal Product – Flexible or Abso­lute? [Regulatives / Guidelines]

posted by PE – UK, 2024-08-20 12:39 (27 d 19:13 ago) – Posting: # 24156
Views: 724

Hi all,

I have a client who is reviewing an 505(b)(2) NDA and keen to use the Biostudy in an EU submission. The EU legal framework seems pretty clear, in that you can only use an RMP, for the BioEq study, approved/marketed in Europe.

Any thoughts on providing enough manufacturing evidence to claim EU and US RMPs are equivalent? or is this an absolute given the RMP must be manufactured and marketed in EU?

Thanks

Peter

Complete thread:

UA Flag
Activity
 Admin contact
23,225 posts in 4,879 threads, 1,654 registered users;
29 visitors (0 registered, 29 guests [including 8 identified bots]).
Forum time: 07:52 CEST (Europe/Vienna)

The real purpose of the scientific method is to make sure
nature hasn’t misled you into thinking you know something
you actually don’t know.    Robert M. Pirsig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5